Einstein Healthcare Network, Department of Urology, Philadelphia, PA.
Einstein Healthcare Network, Department of Urology, Philadelphia, PA; Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, PA.
Urology. 2021 Jul;153:156-163. doi: 10.1016/j.urology.2020.11.070. Epub 2021 Jan 23.
To assess prescribing and refilling trends of narcotics in postoperative urology patients at our institution. Although the opioid epidemic remains a public health threat, no series has assessed prescribing patterns across urologic surgery disciplines following discharge.
All urologic surgeries were retrospectively reviewed from May 2017-April 2018. Demographics, comorbidities, and postoperative pain management strategies were analyzed. Narcotics usage following surgery were reported in total morphine equivalents (TME). Opioid refill rate was characterized by medical specialty and stratified by urologic discipline.
817 cases were reviewed. Mean age and TME at discharge was 57±15.6 years and 35.43±19.5 mg, respectively. 13.6% (mean age 55±15.9) received a narcotic refill following discharge (mean TME/refill 37.7±28.9 mg). A higher proportion of patients with a pre-operative opioid prescription received a refill compared to opioid naïve patients (38.2% vs 21.6%, P < .01). Refill rate did not differ between urologic subspecialties (P = .3). Urologists were only responsible for 20.4% of all refills filled, despite all patients continuing follow-up with their surgeon. Procedures with the highest rates of post-operative refills were in oncology, male reconstruction/trauma and endourology. Patients with a history of chronic pain (OR 1.9, CI 1.1-3.3) preoperative narcotic prescription (OR 1.6, CI 1.0-2.6), and higher ASA score (OR 1.8, CI 1.6-2.8) were more likely to obtain a postoperative opioid prescription refill.
Approximately 1 in 7 postoperative urology patients receive a postoperative narcotics refill; however, nearly two-thirds receive refills exclusively from non-urologic providers. Attempts to avoid overprescribing of postoperative narcotics need to account for both surgeon and nonsurgeon sources of opioid refills.
评估我院泌尿外科术后患者阿片类药物的开具和续方趋势。尽管阿片类药物滥用危机仍然是公共卫生威胁,但尚无系列研究评估泌尿科手术后各外科专业的处方模式。
回顾性分析 2017 年 5 月至 2018 年 4 月期间的所有泌尿外科手术。分析患者的人口统计学、合并症和术后疼痛管理策略。术后使用的阿片类药物用量以吗啡等效剂量(TME)表示。根据医疗专业和泌尿外科专业对阿片类药物的续方率进行分层。
共回顾 817 例患者。出院时的平均年龄和 TME 分别为 57±15.6 岁和 35.43±19.5mg。13.6%(平均年龄 55±15.9 岁)在出院后开具了阿片类药物续方(平均 TME/续方 37.7±28.9mg)。与未使用过阿片类药物的患者相比,术前使用过阿片类药物的患者续方的比例更高(38.2% vs 21.6%,P<.01)。泌尿外科亚专科之间的续方率无差异(P=0.3)。尽管所有患者都继续接受外科医生的随访,但只有 20.4%的阿片类药物续方由泌尿科医生开具。术后需要续方比例最高的手术是肿瘤、男性重建/创伤和内镜泌尿外科手术。有慢性疼痛史(OR 1.9,CI 1.1-3.3)、术前有阿片类药物处方(OR 1.6,CI 1.0-2.6)和较高 ASA 评分(OR 1.8,CI 1.6-2.8)的患者更有可能获得术后阿片类药物处方续方。
大约每 7 名泌尿外科术后患者中就有 1 名患者需要开具术后阿片类药物续方;然而,近三分之二的患者仅从非泌尿外科医生处获得续方。为避免术后阿片类药物过度开具,需要考虑外科医生和非外科医生的阿片类药物续方来源。